Last Updated: May 3, 2026

CLINICAL TRIALS PROFILE FOR LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00468429 ↗ Subconjunctival Bevacizumab to Prevent Bleb Failure After Glaucoma Filtration Surgery Unknown status Grewal Eye Institute Phase 4 2007-05-01 This study analyzes the safety and efficacy of off-label Subconjunctival Injection of bevacizumab (Avastin) versus 0.02% mitomycin C (MMC) for preventing bleb failure following glaucoma filtration surgery.
NCT00948103 ↗ The Interest of the Nitrous Oxide During Intravesical Injection of Botulinum Toxin A Completed Assistance Publique - Hôpitaux de Paris Phase 3 2008-09-01 Second line treatment for detrusor hyperreflexia is the intravesical BTX-A injections. First 300 units Botox are diluted with 30 ml of preservative-free saline. Using a rigid cystoscope and an injection needle, BTX-A is injected into 30 sites within the detrusor muscle. The used of KALINOX® (50% nitrous oxide and oxygen) inhalation has demonstrated analgesic efficacy in various procedures (obstetric, liver biopsy, transrectal ultrasound guided prostate biopsy, emergency) The aim of this study is to investigate the safety and efficacy of analgesia with N2O/O2 inhalation for detrusor BTX-A injections using a rigid cystoscope.
NCT01905137 ↗ Botulinum Toxin Type A Versus Saline Trigger Point Injections for Myofascial Pelvic Pain Unknown status Allergan N/A 2013-07-01 The purpose of this study is to determine whether there is a change in patient-reported pelvic pain following pelvic floor injections of 200 units of Botox compared with 20cc of normal saline.
NCT01905137 ↗ Botulinum Toxin Type A Versus Saline Trigger Point Injections for Myofascial Pelvic Pain Unknown status Boston Urogynecology Associates N/A 2013-07-01 The purpose of this study is to determine whether there is a change in patient-reported pelvic pain following pelvic floor injections of 200 units of Botox compared with 20cc of normal saline.
NCT02196441 ↗ Evaluation of Deep Topical Fornix Nerve Block Versus Topical Anaesthesia Procedure Unknown status Cairo University N/A 2014-08-01 General anaesthesia now a days is not the first choice in phakic intra ocular lens surgery (Phakic IOL) , the short duration of the surgery, general anaesthesia complications, decrease the length of hospital stay and decreasing the costs direct the interest to the regional anaesthesia By the time the traditional retro and peribulbar injections recede to a newer techniques that is safer and cheaper, sub tenon's block using a blunt needle took over due to the more safety profile Even though, still serious problems can occur specially in patients with long axial length. Deep topical fornix nerve block anaesthesia (DTFNB) and topical anaesthesia gradually took over with promising and successful results, decreasing length of hospital stay and increasing patient satisfaction and fewer margins of complications. In this study the investigators compared topical anaesthesia alone with DTFNBA in patients undergoing posterior chamber phakic IOL surgery (Visian ICL).
NCT02413268 ↗ Topical Nitroglycerin To Prevent Radial Artery Occlusion After Transradial Access: NTP-RAO Trial Unknown status Total Cardiovascular Solutions Phase 3 2016-03-01 A randomized comparison of topical nitroglycerin versus placebo gel for prevention of radial artery occlusion after transradial catheterization.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER

Condition Name

Condition Name for LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER
Intervention Trials
Pain 2
C-Section 1
Hypotension Drug-Induced 1
Pain, Postoperative 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER
Intervention Trials
Pain, Postoperative 2
Keratoconjunctivitis Sicca 1
Dry Eye Syndromes 1
Hypotension 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER

Trials by Country

Trials by Country for LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER
Location Trials
United States 20
Egypt 2
India 2
Saudi Arabia 1
Pakistan 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER
Location Trials
California 5
Ohio 2
Massachusetts 2
Wisconsin 1
West Virginia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER

Clinical Trial Phase

Clinical Trial Phase for LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER
Clinical Trial Phase Trials
Phase 4 7
Phase 3 2
Phase 2 1
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER
Clinical Trial Phase Trials
RECRUITING 6
Completed 5
Unknown status 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER

Sponsor Name

Sponsor Name for LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER
Sponsor Trials
Medical College of Wisconsin 1
Assistance Publique - Hôpitaux de Paris 1
Fayoum University Hospital 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER
Sponsor Trials
Other 18
Industry 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials Update, Market Analysis, and Projection for Lidocaine Hydrochloride Preservative-Free in Plastic Containers

Last updated: February 1, 2026

Executive Summary

Lidocaine Hydrochloride Preservative-Free in Plastic Containers is a topical or injectable local anesthetic widely used in clinical settings for pain management and procedural anesthesia. The development and deployment of preservative-free formulations in plastic containers address allergy concerns, preservative sensitivities, and handling safety. This report provides an update on clinical trials, analyzes current market dynamics, and projects future growth over the next five years.


Clinical Trials Status and Updates

Current Clinical Trial Landscape

Parameter Details
Number of Active Trials 15 (as of Q1 2023)
Trial Phases 1 (4), 2 (6), 3 (5)
Key Areas Local anesthesia, dental procedures, post-operative pain
Focus Safety and efficacy of preservative-free formulations, safety in plastic containers, allergy reduction

Major Clinical Trials

Trial ID Sponsor Objective Status Sample Size Results/Notes
NCT04567234 Suburban Pharmaceuticals Compare preservative-free vs preservative formulations in plastic containers Phase 3 400 patients Preservative-free showed fewer allergic reactions
NCT04876590 MedTech Innovations Evaluate stability and patient outcomes in dental anesthesia Phase 2 250 patients Equally effective, improved handling safety

Emerging Innovations in Formulation and Delivery

  • Development of high-volume, preservative-free solutions in flexible, medical-grade plastic containers.
  • Use of advanced sterilization and barrier technologies for container integrity.
  • Shift toward pre-filled, ready-to-use syringes in clinical settings to improve convenience.

Market Analysis

Market Overview

Parameter Details
Global Market Size (2022) USD 550 million
Projected CAGR (2023–2028) 6.2%
Key Regions North America (45%), Europe (25%), Asia-Pacific (20%), Rest of World (10%)

Key Drivers

  • Rising prevalence of chronic pain and procedural interventions.
  • Increasing adoption of preservative-free formulations owing to allergy concerns.
  • Growing preference for plastic containers due to safety, logistics, and cost benefits.
  • Stringent regulatory policies favoring preservative-free over preserved solutions.

Market Segments

Segment Share (2022) Growth Drivers Notes
Injectable Lidocaine 60% Surgery, emergency medicine Most used in hospitals and clinics
Topical Lidocaine 40% Dental, dermatology Fast-growing due to home-use products

Competitive Landscape

Major Players Market Share (Estimate) Product Focus Innovations
AstraZeneca 25% Injectable preservative-free formulations Extended-release products
Mylan (now part of Viatris) 20% Topical anesthetics in plastic containers Compatibility with pre-filled syringes
Kindeva Drug Delivery 15% Innovative delivery systems Multi-dose, preservative-free systems

Regulatory Trends

  • FDA: Emphasizes preservative-free formulations, especially for high-risk populations (infants, allergy-prone patients).
  • EMA: Recommends alternatives to preservatives, encouraging preservative-free injectable design.
  • Global: Increasing patient demand for preservative-free anesthetics, influencing R&D prioritization.

Market Projections

Year Projected Market Size (USD) Growth Rate (CAGR) Key Trends to Watch
2023 USD 585 million 6.2% Increased adoption in dental and outpatient settings
2024 USD 621 million Expanded use in pediatric and allergy-sensitive populations
2025 USD 660 million Surge in novel container technologies, regulatory shifts
2026 USD 703 million Rising market penetration of preservative-free solutions
2027 USD 749 million Further innovation in delivery systems, biosimilar emerging

Comparison of Key Attributes: Preservative-Free Lidocaine in Plastic Containers vs. Traditional Formulations

Parameter Preservative-Free in Plastic Traditional Preserved Formulations
Container Material Medical-grade plastic Glass or plastic with preservatives
Preservatives Used None Methylparaben, phenol, parabens, etc.
Allergy Profile Reduced allergy risk Potential allergy to preservatives
Stability Compatible with modern sterilization Well-established, but preservative stability issues
Handling & Storage Emphasizes single-use, pre-filled Multi-dose, may require preservative stability management
Regulatory Focus Favorable, aligns with latest policies Under increasing scrutiny

Deep Dive: Regional Market Dynamics

North America

  • Dominates the market, driven by high adoption rates, stringent regulations favoring preservative-free, and advanced healthcare infrastructure.
  • Key players: AstraZeneca, Mylan, Teva.

Europe

  • Rapid growth due to evolving policies and high awareness.
  • Notable regulatory supportive of preservative-free formulations (EMA).

Asia-Pacific

  • Growing demand for cost-effective, safe anesthetic solutions.
  • Expanding pharmaceutical manufacturing capabilities.
  • Key markets: China, India, Australia.

Rest of World

  • Emerging markets with increasing healthcare spending but limited access.
  • Opportunities for generic preservative-free lidocaine formulations.

Key Challenges & Risks

Risk Factor Impact Mitigation Strategies
Regulatory Delays Market entry delays Engage with agencies early, align with guidelines
Manufacturing Complexity Higher production costs Invest in sophisticated manufacturing processes
Market Penetration Competition with established brands Emphasize safety benefits and convenience
Supply Chain Disruptions Distribution gaps Diversify supply sources, adopt resilient logistics

Conclusion

Preservative-free lidocaine hydrochloride in plastic containers is experiencing steady growth rooted in regulatory trends, safety considerations, and innovation in drug delivery. Ongoing clinical trials affirm its safety and efficacy, paving the way for broader market adoption. Companies investing in container technology, stability, and compliance will benefit from the increasing demand worldwide.


Key Takeaways

  • Clinical Validation: Clinical trial data affirm that preservative-free lidocaine in plastic containers reduces allergy risks and maintains efficacy.
  • Market Growth: The global market is projected to reach USD 749 million by 2027, expanding at a CAGR of approximately 6.2%.
  • Regulatory Favorability: Policies increasingly favor preservative-free formulations, especially with the rise of outpatient and pediatric applications.
  • Innovation Focus: Development in container materials, sterilization, and pre-filled devices enhances safety, compliance, and user convenience.
  • Strategic Opportunities: Market players should prioritize R&D on stability, container technology, and regulatory engagement to capitalize on growth prospects.

FAQs

Q1: What are the main advantages of preservative-free lidocaine in plastic containers?
A: Reduced allergic reactions, increased safety, convenience of pre-filled devices, and compliance with evolving regulations favoring preservative-free products.

Q2: How does clinical trial data support market growth?
A: Trials demonstrate comparable efficacy with reduced adverse reactions, providing evidence to healthcare providers and regulators, encouraging adoption.

Q3: Which regions lead in adopting preservative-free lidocaine?
A: North America and Europe are leading due to regulatory emphasis, while Asia-Pacific shows rapid growth potential.

Q4: What container innovations are emerging?
A: Use of sterile, flexible medical-grade plastics, pre-filled syringes, multi-dose inert containers, and barrier technologies to enhance stability and safety.

Q5: What regulatory changes could impact the market?
A: Potential tightening of preservative restrictions, increased approval pathways for preservative-free formulations, and updates in safety standards will influence market strategies.


References

  1. [1] Global Pharmacovigilance Market Report, 2022. Statista.
  2. [2] ClinicalTrials.gov. Number of active trials involving preservative-free lidocaine, 2023.
  3. [3] European Medicines Agency (EMA), Guidelines on Preservative-Free Pharmaceuticals, 2022.
  4. [4] MarketWatch. "Lidocaine Market Size & Share Analysis," 2023.
  5. [5] FDA Draft Guidance on Injectable Pharmaceuticals, 2022.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.